Lotus Pharmaceutical Co (美時化學製藥), which makes and distributes oral and injection medicine, yesterday inked a cooperation deal with US-based drug maker Alvogen Group Inc, allowing Alvogen to acquire around 60 percent of its shares for US$200 million.
The deal still has to be approved by shareholders of Lotus Pharmaceutical, the company said.
“Lotus Pharmaceutical can achieve greater market access through this cooperation, and both companies can have a stronger portfolio because we have a different product-mix,” company chairman Charles Lin (林東和) said at a press conference.
Asked whether Lotus Pharmaceutical will have less control over its future direction, Lin said Alvogen and Lotus Pharmaceutical will both have a say in the company’s future decisions.
The Taiwan-based firm plans to sell up to 154.11 million shares at NT$39.5 per share to Alvogen through a private placement after the deal is approved by its shareholders.
Lotus Pharmaceutical plans to use the proceeds to finance research and development and set up international retail chains, especially in the US, the company said.
Both parties have agreed that Lotus Pharmaceutical will make drugs for Alvogen, especially those to go on sale in Asia.
The companies are to also cooperate on strategies for the markets in China, India, Thailand, Myanmar, Singapore, Malaysia and South Korea.
“Our costs for making drugs for the Asian market are lower than Alvogen’s, and we will start by making Alvogen’s oral medicine for the treatment of cancer,” Lotus Pharmaceutical chief finance officer Ben Chung (鍾啟川) said.
Lotus Pharmaceutical makes 300 million pills a year.
Alvogen is to assist Lotus Pharmaceutical to apply for drug permits in the US and sell its drugs in the country.
It also plans to help Lotus Pharmaceutical to enhance its research and development capabilities, the Taiwanese company said.
Alvogen’s annual revenue is about US$400 million, Lotus Pharmaceutical said, adding that Alvogen’s sales to the US and Europe each account for 50 percent of its revenue.
From January through last month, Lotus Pharmaceutical posted revenue of NT$577.46 million, up 29.39 percent from a year ago, according to the company’s filing to the Taiwan Stock Exchange.
“One of our cancer treatment drugs successfully entered the Japanese market in October, and its sales will help our revenue to grow significantly, starting November,” Lin said.
During the first nine months of this year, the company reported profit of NT$26.99 million, or NT$0.47 per share, up from losses of NT$116.47 million, or NT$2.62 per share a year ago, according to company data.
Lotus Pharmaceutical’s shares rose 1.2 percent yesterday on the GRETAI Securities Market, outperforming the over-the-counter market’s 0.68 percent decline.
Intel Corp chief executive officer Lip-Bu Tan (陳立武) is expected to meet with Taiwanese suppliers next month in conjunction with the opening of the Computex Taipei trade show, supply chain sources said on Monday. The visit, the first for Tan to Taiwan since assuming his new post last month, would be aimed at enhancing Intel’s ties with suppliers in Taiwan as he attempts to help turn around the struggling US chipmaker, the sources said. Tan is to hold a banquet to celebrate Intel’s 40-year presence in Taiwan before Computex opens on May 20 and invite dozens of Taiwanese suppliers to exchange views
Application-specific integrated circuit designer Faraday Technology Corp (智原) yesterday said that although revenue this quarter would decline 30 percent from last quarter, it retained its full-year forecast of revenue growth of 100 percent. The company attributed the quarterly drop to a slowdown in customers’ production of chips using Faraday’s advanced packaging technology. The company is still confident about its revenue growth this year, given its strong “design-win” — or the projects it won to help customers design their chips, Faraday president Steve Wang (王國雍) told an online earnings conference. “The design-win this year is better than we expected. We believe we will win
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) is expected to share his views about the artificial intelligence (AI) industry’s prospects during his speech at the company’s 37th anniversary ceremony, as AI servers have become a new growth engine for the equipment manufacturing service provider. Lam’s speech is much anticipated, as Quanta has risen as one of the world’s major AI server suppliers. The company reported a 30 percent year-on-year growth in consolidated revenue to NT$1.41 trillion (US$43.35 billion) last year, thanks to fast-growing demand for servers, especially those with AI capabilities. The company told investors in November last year that
Power supply and electronic components maker Delta Electronics Inc (台達電) yesterday said it plans to ship its new 1 megawatt charging systems for electric trucks and buses in the first half of next year at the earliest. The new charging piles, which deliver up to 1 megawatt of charging power, are designed for heavy-duty electric vehicles, and support a maximum current of 1,500 amperes and output of 1,250 volts, Delta said in a news release. “If everything goes smoothly, we could begin shipping those new charging systems as early as in the first half of next year,” a company official said. The new
RSS